These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33503564)

  • 1. Simultaneous spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in recently approved FDA pharmaceutical preparation using artificial neural networks and genetic algorithm artificial neural networks.
    Attia KAM; El-Abasawi NM; El-Olemy A; Abdelazim AH; Goda AI; Shahin M; Zeid AM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Apr; 251():119465. PubMed ID: 33503564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of different chemometric assisted models for spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
    Abdelazim AH; Shahin M; Abu-Khadra AS
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 May; 252():119540. PubMed ID: 33588366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of different mathematical models for simultaneous UV spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
    Abdelazim AH; Ramzy S; Abdelzaher AM; Shahin M
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Feb; 267(Pt 1):120536. PubMed ID: 34739999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models.
    Zeid AM; Abdelazim AH; Shahin M
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 May; 252():119505. PubMed ID: 33561683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrophotometric assessment of the brand new antiviral combination: Sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation.
    Rezk MR; Monir HH; Marzouk HM
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Apr; 213():159-166. PubMed ID: 30685554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers.
    Elkady EF; Aboelwafa AA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():116-124. PubMed ID: 30384188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
    Miller MM
    Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
    Younossi ZM; Stepanova M; Gordon S; Zeuzem S; Mann MP; Jacobson I; Bourliere M; Cooper C; Flamm S; Reddy KR; Kowdley K; Younossi I; Hunt S
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):567-574.e6. PubMed ID: 29155352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
    Li C; Li X; Zhu X; Zhang H; Shen G; Kersey K; Ding Y
    Clin Ther; 2020 Mar; 42(3):448-457. PubMed ID: 32115243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intelligent method based on feed-forward artificial neural network and least square support vector machine for the simultaneous spectrophotometric estimation of anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid.
    Keyvan K; Sohrabi MR; Motiee F
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Dec; 263():120190. PubMed ID: 34332240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariable Manipulation of Spectrophotometric Data with Genetic Algorithm Selection for Novel Quantitative Resolution of Five Antiviral Drugs in Their Pharmaceutical Products.
    Essam HM; Morsi AM; El-Zeiny MB
    J AOAC Int; 2021 Jun; 104(3):571-578. PubMed ID: 33492390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
    Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
    Lalanne S; Jézéquel C; Tron C; Verdier MC; Mercerolle M; Pronier C; Guyader D; Lemaitre F
    Ther Drug Monit; 2020 Apr; 42(2):163-164. PubMed ID: 32195986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thin-layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma.
    Derayea SM; Abdel-Lateef MA; Omar MA; Ali R
    Luminescence; 2020 Nov; 35(7):1048-1055. PubMed ID: 32350964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
    Ruane P; Strasser SI; Gane EJ; Hyland RH; Shao J; Dvory-Sobol H; Tran T; Stamm LM; Brainard DM; Nyberg L; Shafran S
    J Viral Hepat; 2019 Jun; 26(6):770-773. PubMed ID: 30663168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Sucher AJ; Hemstreet BA
    Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.